Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
Vistagen (Nasdaq: VTGN) reported a narrower net loss for its fiscal 2027 second quarter while outlining further fasedienol development plans. For the quarter ended September 30, 2026, net loss was $10.740 million, versus $19.417 million a year earlier. Revenue fell to $138,000 from $258,000, while research and development expense fell to $6.554 million from $15.915 million.
Following FDA feedback, Vistagen plans future Phase 3 development for overall social anxiety disorder treatment rather than only acute treatment, using recommendations on the Liebowitz Social Anxiety Scale. Preliminary PALISADE-4 open-label extension data showed improvement over four months. Cash, cash equivalents and marketable securities totaled $20.0 million at September 30. Vistagen expects funding into 2027, but not beyond one year from the announcement, and has implemented cost-management initiatives.
Vistagen (Nasdaq: VTGN) received FDA feedback on potential Phase 3 development paths for fasedienol in adults with social anxiety disorder.
The discussion covered proposed use of the Liebowitz Social Anxiety Scale as the primary endpoint, a measure of social anxiety. FDA recommendations included interim assessments examining whether acute effects could translate into longer-term functional improvement. Vistagen plans to incorporate electronic diaries and qualitative patient surveys and submit a revised protocol. The company plans to focus future development on the general social anxiety disorder population and overall treatment, rather than acute treatment alone.
Vistagen (VTGN) has selected GATC Health to apply predictive artificial intelligence across its lead clinical-stage drug development programs.
The collaboration brings GATC Health’s Operon platform and Derisq predictive intelligence capabilities to planning for a potential next Phase 3 study of fasedienol for social anxiety disorder. The study would use the Liebowitz Social Anxiety Scale (LSAS) as its primary measure of efficacy. The collaboration also covers potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes.
Vistagen says it is incorporating predictive insights into fasedienol protocol development alongside its experience and existing datasets. The companies are using predictive modeling to complement traditional development approaches and inform study design, pipeline prioritization and resource allocation.
SRX Global (SRXH) added an investment in Onconetix (ONCO) and updated shareholders on the liquidation of two portfolio holdings.
The holdings are Vistagen Therapeutics (VTGN) and Greenland Mines (GRML). SRX said it added Onconetix in anticipation of the closing of Onconetix's previously announced agreement to acquire Realbotix. Realbotix developed Vinci, an AI vision system that places cameras and tracking lenses inside robotic eyes. The system is described as detecting motion, recognizing returning users and identifying objects or colors.
Vistagen (VTGN) reported exploratory fasedienol findings in people with very severe social anxiety disorder from two placebo-controlled studies. Very severe social anxiety was defined as a baseline Liebowitz Social Anxiety Scale score of 95 or higher.
In a post-hoc analysis of the Phase 3 PALISADE-4 trial, this subgroup had significantly lower average anxiety scores during a public speaking challenge with fasedienol than with placebo, although the trial missed its primary endpoint in the full population. A prespecified subgroup analysis in a Phase 2a repeat-dose study found a significant improvement after one dose and a greater numerical improvement after a second dose given 10 minutes later.
Vistagen (VTGN) reported preliminary positive data from the open-label extension (OLE) portion of its Phase 3 PALISADE-4 study of fasedienol nasal spray for the acute treatment of social anxiety disorder.
In 322 adults using 3.2 µg fasedienol as needed, up to six times daily for up to 12 months, treatment was well-tolerated, with a 1.6% discontinuation rate due to adverse events and no discontinuations or serious adverse events attributed to fasedienol. More than 95% of treatment-emergent adverse events were mild or moderate; headache (18.0%), upper respiratory tract infection (9.9%), rhinorrhoea (7.1%), and oropharyngeal pain (5.3%) were the most common. No safety signals of concern were seen in labs, ECGs, exams, or vital signs.
Exploratory efficacy over four months showed clinically relevant improvements on the clinician-rated LSAS (mean improvement rising from 20.2 to 31.4 points; ≥20‑point responders increasing from 44% to 65%) and patient-reported SPIN (mean improvement rising from 10.5 to 14.9 points; ≥10‑point responders increasing from 45% to 59%). The company is preparing to meet with the FDA this quarter to discuss a proposed new registrational Phase 3 trial in social anxiety disorder.
Vistagen (VTGN) will present Phase 3 fasedienol nasal spray data showing a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder at Psych Congress in New Orleans on September 17–18, 2026.
The poster, number 230, is titled “Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores ≥95: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials.”
Vistagen (Nasdaq: VTGN) reported fiscal 2027 first quarter results for the period ended June 30, 2026, and provided a corporate update focused on its pherine pipeline. Revenue rose to $1.5 million, mainly from $1.2 million recognized upon expiration of an exclusive negotiation agreement with Fuji Pharma. R&D expense declined to $10.9 million from $11.7 million, and G&A fell to $3.9 million from $4.4 million, reducing net loss to $13.0 million from $15.1 million year over year.
Cash, cash equivalents, and marketable securities totaled $31.7 million, which the company believes will fund operations into 2027, but for less than one year from now. Clinically, Vistagen reported exploratory and post‑hoc analyses for fasedienol in social anxiety disorder, achieved ICH-recommended exposure levels, and is preparing for an FDA meeting on a potential registration-directed path. The FDA also issued a “Study May Proceed” letter for refisolone in menopausal hot flashes. The company appointed Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D., to its Board, and continued cost-management initiatives.
Vistagen (Nasdaq: VTGN) reported topline results from an exploratory Phase 2, three‑arm, randomized, double‑blind, placebo‑controlled study (N=61) of intranasal fasedienol for acute treatment of social anxiety disorder induced by a public speaking challenge. The trial compared repeat 3.2 µg dosing ten minutes apart, single 3.2 µg dosing, and placebo.
The study met its primary safety objective, with repeat dosing showing safety and tolerability comparable to single dosing and no new safety findings. Numerically greater reductions in subjective units of distress (SUDS) versus placebo were observed for pooled, repeat, and single‑dose fasedienol, though overall group differences were not statistically significant (p=0.2). In a prespecified very severe subgroup (baseline LSAS ≥95), pooled and single‑dose fasedienol showed nominally statistically significant SUDS improvements versus placebo (p=0.04 and p=0.05).
Responder rates on CGI‑I and PGI‑C were directionally higher for fasedienol than placebo, with repeat‑dose responder rates more than twice placebo overall and at least four times placebo in the very severe subgroup. A prespecified exploratory analysis of anticipatory anxiety showed larger SUDS reductions for pooled and repeat‑dose fasedienol versus placebo, with nominal statistical significance (p=0.03 and p=0.01). Vistagen indicated these data, together with prior Phase 2 and Phase 3 results, will inform discussions with the FDA about a potential registrational pathway for fasedienol.
SRX Global (NYSE American: SRXH) announced it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), described as a late clinical-stage biopharmaceutical company developing nose-to-brain intranasal product candidates, called pherines, to address neurocircuitry involved in neuroscience indications.
According to SRX Global, it views Vistagen shares as undervalued and is open to constructive engagement with Vistagen’s leadership team and Board of Directors to discuss ideas for unlocking shareholder value. SRX Global describes itself as an AI-driven investment platform that uses proprietary technology, data analytics, and disciplined capital allocation to invest in high-conviction operating companies, strategic assets, and technology-enabled opportunities across multiple sectors.